This content was accurate at the time of release, 26 December 2021. Accreditation for this course expired on 27 December 2022. If you would still like an activity completion certificate, send your request to firstname.lastname@example.org.
This case study features expert discussion surrounding a real HCM patient and is designed to raise disease awareness and provide you with a practical understanding of how HCM can be diagnosed and appropriately managed. It assists clinicians in community practice or those with an interest in HCM management to:
- improve recognition of HCM
- provide appropriate management strategies for heart failure symptoms and recognise limitations
- know when referral to an HCM expert center is appropriate
This case study discussion is designed to be completed in 45 minutes.
Target audience: Family/general physicians, general/community cardiologists, cardiac nurses, paediatricians, paediatric nurses, genetic counselors
Funding disclosure: This activity is supported by educational grant funding from Bristol Myers Squibb, Cytokinetics and Sanofi.
Learners may participate in this educational activity free of charge.
- Clinical presentation and symptoms
- Diagnostic criteria and features
- Exclusion of other conditions
- Misdiagnosis and pharmacotherapy
By the end of this activity, learners will be able to:
- List symptoms that raise suspicion of HCM and apply to an example patient
- Explain the cardiovascular imaging features that support a clinical diagnosis of HCM
- Recall conditions that must be ruled out during the differential diagnosis of HCM and apply this to an example patient.
Accreditation for this course has expired. You may view the program, but CME / CE is no longer available and no certificate will be issued.
Dr John Lynn Jefferies, MD, Professor and Chief of Advanced Heart Failure and Transplant Cardiology, Cardiovascular Disease, Methodist University Hospital/ University of Tennessee, St Jude Children’s Research Hospital, has received financial compensation for consulting for Abbott, Novartis, and Pfizer, and received research grants from Myokardia, Abbott, Novartis, and Pfizer.
Lisa Salberg, Founder and CEO of the Hypertrophic Cardiomyopathy Association (HCMA), has no relevant conflicts of interest to disclose.
Disclosure of educational planners:
Lauren Tebay, BA (mod), PhD, Senior Medical Writer, PCM Scientific, has no relevant conflicts of interest to disclose.
Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant conflicts of interest to disclose.
All relevant financial relationships have been mitigated.